WO2011050206A3 - Compositions and methods for the treatment of sinonasal disorders - Google Patents
Compositions and methods for the treatment of sinonasal disorders Download PDFInfo
- Publication number
- WO2011050206A3 WO2011050206A3 PCT/US2010/053616 US2010053616W WO2011050206A3 WO 2011050206 A3 WO2011050206 A3 WO 2011050206A3 US 2010053616 W US2010053616 W US 2010053616W WO 2011050206 A3 WO2011050206 A3 WO 2011050206A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sinonasal
- compositions
- treatment
- methods
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Disclosed herein are compositions and methods for the treatment of sinonasal and/or nasopharyngeal diseases or conditions with active agent compositions and formulations administered locally to an individual afflicted with a sinonasal or nasopharyngeal disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted sinonasal structure(s).
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25378209P | 2009-10-21 | 2009-10-21 | |
US61/253,782 | 2009-10-21 | ||
US25537909P | 2009-10-27 | 2009-10-27 | |
US61/255,379 | 2009-10-27 | ||
US25578309P | 2009-10-28 | 2009-10-28 | |
US25578009P | 2009-10-28 | 2009-10-28 | |
US61/255,780 | 2009-10-28 | ||
US61/255,783 | 2009-10-28 | ||
US29717010P | 2010-01-21 | 2010-01-21 | |
US29713810P | 2010-01-21 | 2010-01-21 | |
US61/297,170 | 2010-01-21 | ||
US61/297,138 | 2010-01-21 | ||
US36428710P | 2010-07-14 | 2010-07-14 | |
US61/364,287 | 2010-07-14 | ||
US36667710P | 2010-07-21 | 2010-07-21 | |
US61/366,677 | 2010-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011050206A2 WO2011050206A2 (en) | 2011-04-28 |
WO2011050206A3 true WO2011050206A3 (en) | 2011-09-22 |
Family
ID=43900967
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/053217 WO2011049960A2 (en) | 2009-10-21 | 2010-10-19 | Compositions and methods for the treatment of sinonasal disorders |
PCT/US2010/053616 WO2011050206A2 (en) | 2009-10-21 | 2010-10-21 | Compositions and methods for the treatment of sinonasal disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/053217 WO2011049960A2 (en) | 2009-10-21 | 2010-10-19 | Compositions and methods for the treatment of sinonasal disorders |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2011049960A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1962805T3 (en) | 2005-12-08 | 2016-09-26 | Insmed Inc | Lipid-based compositions of the anti-infective agents for the treatment of lung infections |
AU2012211514B2 (en) * | 2006-10-24 | 2014-07-31 | Aradigm Corporation | Concentrated, inhalable ciprofloxacin formulation |
US8119156B2 (en) | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
EP2731590B1 (en) | 2011-07-13 | 2018-05-23 | The Foundry, LLC | Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets |
SG11201407676VA (en) * | 2012-05-21 | 2015-03-30 | Agency Science Tech & Res | A dry powder formulation |
AU2013352259B2 (en) | 2012-11-29 | 2018-06-14 | Insmed Incorporated | Stabilized vancomycin formulations |
PL2759290T3 (en) | 2013-01-24 | 2020-03-31 | Merz Pharma Gmbh & Co. Kgaa | Sprayable liquid composition for nasal application having an increased local retention time |
DE202013000748U1 (en) | 2013-01-24 | 2013-02-19 | Merz Pharma Gmbh & Co. Kgaa | Sprayable liquid preparation for especially nasal application with increased local residence time |
DE102013001151A1 (en) | 2013-01-24 | 2014-07-24 | Merz Pharma Gmbh & Co. Kgaa | Nasal preparation, used to topical, protective, nurturing/supporting application to treat irritation/swelling in nasal mucosa due to e.g. allergies, includes mineral salt, water, alcohols, poloxamer surfactants, and additives e.g. enzyme |
US20140371305A1 (en) * | 2013-06-14 | 2014-12-18 | Professional Compounding Centers Of America | Mupirocin Antibiotic Composition |
US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
AU2014340568B2 (en) | 2013-10-22 | 2017-02-02 | Aradigm Corporation | Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile |
ES2926985T3 (en) | 2014-05-15 | 2022-10-31 | Insmed Inc | Methods for treating nontuberculous mycobacterial lung infections |
KR20170021353A (en) | 2014-07-03 | 2017-02-27 | 오토노미, 인코포레이티드 | Sterilization of ciprofloxacin composition |
CN104341405B (en) * | 2014-09-25 | 2016-09-14 | 武汉大学 | The preparation method of a kind of compound with suppression A beta peptide aggregation activity and purposes |
WO2017105356A1 (en) | 2015-12-18 | 2017-06-22 | Ak-Kim Kimya Sanayi Ve Ticaret Anonim Sirketi | Hollow fiber membrane module |
CN105902543B (en) * | 2016-04-28 | 2019-02-12 | 华北制药股份有限公司 | A kind of high-purity mezlocillin sodium preparation and preparation method thereof |
US20180071281A1 (en) * | 2016-08-19 | 2018-03-15 | Gerbe Labs Inc. | Treating chronic rhinosinusitis |
EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
CN110141559A (en) * | 2019-06-18 | 2019-08-20 | 浦易(上海)生物技术有限公司 | It is a kind of for the pastille slow-release particle of schneiderian membrane and its application |
CN115666630A (en) * | 2020-04-08 | 2023-01-31 | 诺斯楚姆制药有限责任公司 | Compositions and methods for treating respiratory viral infections using interferon |
US20220135653A1 (en) * | 2020-11-05 | 2022-05-05 | Bravado Pharmaceuticals, LLC | Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections |
CN113456580B (en) * | 2021-07-21 | 2024-03-22 | 沈阳化工大学 | Resveratrol in-situ gel preparation and characterization method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131315A2 (en) * | 1983-05-13 | 1985-01-16 | ISTITUTO DE ANGELI S.p.A. | Nasal preparations comprising anticholinergic quaternary ammonium salts |
US5935604A (en) * | 1993-05-20 | 1999-08-10 | Danbiosyst Uk Limited | Nasal drug delivery composition containing nicotine |
-
2010
- 2010-10-19 WO PCT/US2010/053217 patent/WO2011049960A2/en active Application Filing
- 2010-10-21 WO PCT/US2010/053616 patent/WO2011050206A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0131315A2 (en) * | 1983-05-13 | 1985-01-16 | ISTITUTO DE ANGELI S.p.A. | Nasal preparations comprising anticholinergic quaternary ammonium salts |
US5935604A (en) * | 1993-05-20 | 1999-08-10 | Danbiosyst Uk Limited | Nasal drug delivery composition containing nicotine |
Also Published As
Publication number | Publication date |
---|---|
WO2011049960A2 (en) | 2011-04-28 |
WO2011049960A9 (en) | 2011-08-18 |
WO2011050206A2 (en) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011050206A3 (en) | Compositions and methods for the treatment of sinonasal disorders | |
WO2010011609A3 (en) | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | |
WO2010074992A3 (en) | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | |
WO2011049958A3 (en) | Modulation of gel temperature of poloxamer-containing formulations | |
WO2010008995A3 (en) | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders | |
WO2010011466A3 (en) | Controlled-release cns modulating compositions and methods for the treatment of otic disorders | |
WO2012103038A9 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
WO2010011605A3 (en) | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | |
WO2012145133A3 (en) | Occlusion-crossing devices, imaging, and atherectomy devices | |
WO2012083017A3 (en) | Controlled release oral dosage forms of poorly soluble drugs and uses thereof | |
MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
WO2010083239A3 (en) | Therapeutic modulation of vaginal epithelium boundary lubrication | |
EA202091999A3 (en) | APPLICATION OF DPP IV INHIBITORS | |
EP2358378A4 (en) | Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof | |
WO2013052647A3 (en) | Formulations and uses of retinoic acid receptor selective agonists | |
CY1112320T1 (en) | TAPENDADOL TITLE | |
WO2010151755A3 (en) | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 | |
MX2016002408A (en) | Treatment of pediatric otic disorders. | |
WO2009109613A3 (en) | 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | |
MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
WO2011119227A3 (en) | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients | |
WO2009109616A8 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10825702 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10825702 Country of ref document: EP Kind code of ref document: A2 |